Plain-English translation of NCT07802678 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This study looks at whether people with rheumatoid arthritis can safely stop taking methotrexate or leflunomide—common arthritis medications—while continuing their TNF inhibitor injection or infusion. Right now, most patients take both medications together to control inflammation. This trial wants to know if using just the TNF inhibitor alone works just as well for people whose arthritis is already well controlled.
Many people with arthritis get tired of taking multiple medications, dealing with side effects like stomach problems and fatigue, and having frequent blood tests to monitor their treatment. This study explores whether reducing to one medication could give patients relief from these burdens while keeping their arthritis under control.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to either stop taking your second arthritis medication (methotrexate or leflunomide) while continuing your TNF inhibitor, or to keep taking both medications. Either way, you'll continue coming to regular clinic visits for 24 months where your arthritis will be monitored with blood tests and disease activity assessments. If you're in the medication-reduction group and your arthritis flares up, your doctor can restart the medication you stopped.
AI-generated summary from trial data · Sep 5, 2026 · Not medical advice
Netherlands